Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Saxagliptin backed for use in Welsh diabetes treatment  

  • Comment

A new drug has been recommended in Wales for use in triple therapy for type 2 diabetes patients.

The DPP-4 inhibitor saxagliptin (Onglyza) has been recommended by the All Wales Medicines Strategy Group for use as part of a triple therapy treatment combination for type 2 diabetes.

Saxagliptin is recommended in NHS Wales for adult type 2 diabetes patients aged 18 years and older, in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate blood glucose control.

Around 12% of type 2 diabetes patients are currently taking triple therapy regimens, with about 40% of these taking a combination of metformin, a sulphonylurea and a DPP-4 inhibitor.

The strategy group’s recommendation follows a triple therapy licence granted for the product by the European Medicine Agency in January 2013.

The drug is manufactured by Bristol-Myers Squibb and AstraZeneca, which both welcomed the decision.

 

Are you able to Speak Out Safely? Sign our petition to put pressure on your trust to support an open and transparent NHS.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs